HeartBeam Reaches 'Significant Turning Point' After FDA Clearance

Analysts upgrade company to Buy, raise price target on regulatory progress and commercialization transition

Mar. 31, 2026 at 6:50pm

Got story updates? Submit your updates here. ›

A dramatic, high-contrast close-up of the intricate inner mechanisms and circuitry of a cardiac monitoring device, conveying the advanced, industrial nature of HeartBeam's innovative technology.HeartBeam's FDA-cleared cardiac monitoring technology represents a new era of portable, data-driven cardiac care.Austin Today

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.'s upgrade of the company from Hold to Buy and raising of its 12-month price target to $4 from $1, citing regulatory progress and the company's transition toward commercialization.

Why it matters

The article highlights a significant turning point for HeartBeam following FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment, which resolved an earlier regulatory setback and allowed the company to transition to commercial-stage status.

The details

The report states, 'We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection.' The article notes that the FDA clearance was a key milestone for HeartBeam, enabling the company to move forward with commercialization of its technology designed to transform cardiac care by providing powerful cardiac insights wherever the patient is.

  • HeartBeam received FDA clearance for its 12-lead ECG synthesis software in December 2025.
  • In February 2026, Joseph Gunnar & Co. upgraded HeartBeam to Buy and raised its 12-month price target to $4.

The players

HeartBeam Inc.

A medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions.

Joseph Gunnar & Co.

A financial services firm that provides research, investment banking, and other services. The firm recently upgraded HeartBeam to Buy and raised its price target on the company.

Got photos? Submit your photos here. ›

The takeaway

HeartBeam's FDA clearance for its 12-lead ECG synthesis software represents a significant milestone, allowing the company to transition to commercial-stage status and signaling a turning point as it works to transform cardiac care through its innovative technology.